ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2026
Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells.
Review in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Improving recombinant protein productivity in CHO cells via multi-omics data integration.Bioresources and bioprocessing · 2026Review
- The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Mammalian cell lines are the preferred host cells for the biopharmaceutical industry. Chinese hamster ovary (CHO) and human embryonic kidney 293 (HEK293) cells are frequently utilized in the production of recombinant therapeutic proteins (RTPs) owing to their capacity to facilitate appropriate protein folding and perform accurate post-translational modifications (PTMs). However, there are still some bottlenecks in the biopharmaceutical process using mammalian cells, including lower productivity, higher production cost and increased risk of contamination compared with bacterial or yeast expression systems. In addition to vector, media and bioprocess optimization, advances in host cell engineering including gene overexpression, knockout and knockdown have significantly advanced cell-line development. Besides targeting known genes and pathways, miRNA engineering and omics analysis are also employed to enhance mammalian cell culture performance. Optimization of cell engineering and production processes further drives the development of more efficient mammalian cell expression systems. This review systematically summarizes key achievements in cell engineering and offers insights into potential targets and pathways for improving therapeutic protein production in mammalian cells.
Indexed as
Identifiers
41261329What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.